RareCyte® expands liquid biopsy offering with the release of a HER2/ER breast cancer CTC Panel Kit.
RareCyte® launches prostate cancer ARv7 CTC Kit for liquid biopsy analysis.
New RarePlex® Developer Kits for CTC characterization provide researchers flexibility in independent CTC assay development.
RarePlex CTC Developer Staining Kit enables custom CTC assay development by providing the ability to add up to two biomarkers-of-interest to the CTC base detection assay.
RareCyte Pharma Programs support pharma development through our expert product development teams. Our services span the range from RUO product development for pre-clinical and clinical research to IVD support for companion diagnostic co-development.